Abstract
Background and objectives: Overexpression of the cytoskeleton-modulating kinase ROCK1 has been associated with unfavorable outcome in many cancers, but its impact in prostate cancer is largely unknown.Results: A weak ROCK1 staining was found in >90% of normal, and cancerous prostate tissues, but was generally stronger in cancer cells as compared to adjacent normal glands. In cancer, ROCK1 staining was considered weak, moderate, and strong in 22%, 53%, and 18% of cases respectively. Higher ROCK1 expression levels were associated with tumor stage, and Gleason grade, positive nodal stage, positive surgical margin, accelerated cell proliferation and early PSA recurrence in multivariable analysis. ROCK1 up regulation was associated with androgen receptor (AR) expression, TMPRSS2:ERG fusion, genomic deletions of the PTEN tumor suppressor, as well as recurrent deletions at chromosomes 3p, 5q, 6q. Strong ROCK1 staining was found in 3% of AR-negative, but in 27% of strongly AR positive cancers, in 13% of ERG-negative but in 25% of ERG positive cancers, and in 12% of PTEN normal but in 26% of PTEN deleted cancers.Conclusions: This study identifies ROCK1 expression associated with prognosis in prostate cancer.Methods: We tested ROCK1 expression in 12 427 prostate cancer specimens and followed PSA recurrence after prostatectomy.
Highlights
Prostate cancer is the most prevalent cancer in men in Western societies [1]
This study identifies Rho-associated coiled-coil containing kinase 1 (ROCK1) expression associated with prognosis in prostate cancer
That ROCK1 staining was generally higher in cancers than in tumor adjacent normal prostatic tissue argues for a role of ROCK1 up regulation in prostate cancer development
Summary
Prostate cancer is the most prevalent cancer in men in Western societies [1]. the majority of prostate cancers behave in an indolent manner, a small subset is highly aggressive and requires extensive treatment [2]. Established preoperative prognostic parameters are limited to Gleason grade and tumor extent on biopsies, www.aging-us.com serum prostate-specific antigen (PSA), levels and clinical stage. These parameters are statistically strong, but not sufficient to enable optimal treatment decisions in every patient. It is, hoped that a better understanding of disease biology will eventually lead to the identification of clinically applicable molecular markers that enable a more reliable prediction of prostate cancer aggressiveness. Overexpression of the cytoskeleton-modulating kinase ROCK1 has been associated with unfavorable outcome in many cancers, but its impact in prostate cancer is largely unknown
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
